retatrutide phase 2 trial type 2 diabetes results 2024 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Lilly's triple agonist achieves 16.8%

These findings collectively indicate that modulation of the gut microbiotaSCFAGPR axis plays a pivotal role in alleviating DN-associated renal fibrosis, supporting its potential as a microbiota-targeted therapeutic strategy for improving renal outcomes in DN

Fair Use Statement If you'd like to share or report on the findings from this article, please link back to Levity and credit the source

Hormonal fluctuations throughout the menstrual cycle can affect how side effects manifest, with some women reporting that nausea is more pronounced during certain phases of their cycle

Obesity is a chronic disease, and we need to treat it like one, says Sara Velayati, MD, an obesity medicine specialist at the Fleischer Institute Medical Weight Management Center at Montefiore Einstein in the Bronx, New York

Proc Natl Acad Sci U S A 94:196772 Chen F, Lewis W, Hollander JM, Baseler W, Finkel MS (1985) N -acetylcysteine reverses cardiac myocyte dysfunction in HIV-Tat proteinopathy

LAMs differ from other macrophage subtypes by their high lysosomal and phagocytotic activity, thereby preserving tissue integrity under metabolically demanding conditions 29